It eventually led to Still being diagnosed with ATTR amyloidosis, a rare genetic condition that causes heart problems, neuropathy, and ligament and tendon troubles. Since his diagnosis in ...

AMVUTTRA® (vutrisiran) product logo ATTR-CM is a devastating, rapidly progressive, and ultimately fatal disease estimated to affect approximately 150,000 people in the U.S. and over 300,000 ...

Next up is the CARDIO-TTRansform trial on transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Could you explain the significance of this trial and its potential to reshape the treatment ...

“We are pleased to have dosed the first patient with a treatment that has such strong potential to redefine the treatment paradigm for those living with ATTR with polyneuropathy. This is a ...

The approval expands the indication for AMVUTTRA, which now becomes the first and only therapeutic approved by the FDA for the treatment of ATTR-CM and the polyneuropathy of hereditary ...